Good, better, best. Never let it rest. 'Til your good is better and your better is best.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RVIV Looking good Company is engaged in the manufacturing, marketing, sales, and distribution of professional quality hair and skin care products under various trademarks and brands. We are committed to using the highest quality active ingredients found in nature to create professional grade products that simply work. Our products are sold in targeted markets in the United States, Canada, Europe, and Asia.
Investors Take A Closer Look At One Step Vending Corp (OTCMKTS: $KOSK)
$BIXT The device measures 4 parameters and uses an algorithm to calculate the Tissue Metabolic Score. The primary concept that underpins the technology is Oxygen Balance Homeostasis that dates back to 1914. The principal of Oxygen Balance Homeostasis is that organs are unable to increase their activity without a corresponding increase in oxygen consumption delivered by increased blood flow. Monitoring the TMS in certain less vital organs serves a proxy of tissue health in the most vital organs. The MDX viewer uses a minimally invasive multiparametric monitoring device connected to the patient’s urethral wall via a 3-way Foley catheter to measure TMS. When vital organs in the body are stressed, blood flow is diverted from less vital organs to the most vital organs and the TMS will fall. These changes can be measured with the MDX viewer to track tissue oxygenation levels in vital organs. A key case study done in cardiovascular operated patients underwent bypass of the coronary arteries procedure. During this type of operation, the TMS of the Urethral wall decreased significantly and then recovered toward the end of the operation as expected.
$AMHV mission is to become the world's preeminent, vertically integrated "seed-to-table" hemp operation. AMHV develops hybrid hemp cultivars that are genetically designed to produce high CBD yields in a wide variety of geographies. We apply our proprietary seed feminization process to further increase crop production as much as 100%.
$KOSK SUBSIDIARY Corporate Refreshment Services-Micro Markets, Inc.
CRS-Micro Markets, Inc., a provider of a wide range of food and beverage solutions, focuses on the use of self-checkout Micro Market technology.
$OZSC Price accumulation Key Turning Points
DAILY 52-WEEK
2nd Resistance Point 0.1067
1st Resistance Point 0.1033
Last Price 0.1000
1st Support Level 0.0933
2nd Support Level 0.0867
Ozop Surgical Corp. ( $OZSC )premium surgical devices in the rapidly growing field of minimally invasive spine surgery today announced that it will be presenting at the 9th annual LD Micro Invitational on June 5th at 10:20am PST. Michael Chermak, CEO will be presenting and meeting with investors.
$OZSC Latest News :
Ozop Surgical Corp. (OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery today announced that it will be presenting at the 9th annual LD Micro Invitational on June 5th at 10:20am PST. Michael Chermak, CEO will be presenting and meeting with investors.
"This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever- growing community."
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.
About Ozop Surgical Corp.
$RGBP Trades Up Regen BioPharma, Inc
Regen BioPharma, Inc. Responds to Fake News Release
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (RGBP) and (RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Responding to these inquiries the Company reports that it is currently not in any discussions with any other companies regarding a reverse merger.
"This false news release was brought to my attention by a number of people. I have read the news release in question and can state that it is totally untrue," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. "We are focused on our own business model of small molecule immunotherapies for treating cancer and autoimmune disorders."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
$XALL loading Moving good @ 0.0111+0.0005 (+5.19%) with news today
Xalles to Expand Financial Service Offerings
https://finance.yahoo.com/news/xalles-expand-financial-offerings-123000340.html … #Frontpagestocks
$CETX Moving Green - 0.2500+0.0101 (+4.21%)
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--
Sales and Gross Profit for the quarter increased by 16% and 11% respectively
Cemtrex Inc. (CETX), a leading global technology company, announced its second quarter consolidated results of operations for the three and six months ended March 31, 2019.
Second Quarter Highlights:
Total Revenue for the three months ended March 31, 2019 and 2018 was $23,607,497 and $20,413,296, respectively, an increase of $3,194,201, or 16%. Total revenue in the second quarter increased, as compared to total revenue in the same period last year, primarily due to new revenues in the Advanced Technologies Segment, which had no revenues during the same period last year.
Gross Profit for the three months ended March 31, 2019 was $9,449,392 or 40% of revenues as compared to gross profit of $7,383,310 or 36% of revenues for the three months ended March 31, 2018, a percentage basis increase of 11%. Gross profit as a percentage of revenues in the three months ended March 31, 2019 increased as compared to the three months ended March 31, 2018 as the Company works to achieve economies of scale, lower expenses, and shift to products and services with higher margins.
Net income available to common shareholders for the three months ended March 31, 2019 and 2018 was a loss of $1,983,867 and income of $423,471, respectively, a decrease of $2,407,338, or 568%. Net income available to common shareholders decreased due to increased expenses in sales and marketing for the SmartDesk and VR applications in the Advanced Technologies segment as well as the consolidation of the variable interest entity, Vicon Industries, Inc.,
Six Month Ended March 31, 2019 Financial Highlights
Total revenue for the six months ended March 31, 2019 and 2018 was $40,892,041 and $52,795,196, respectively, a decrease of $11,903,155, or 23% primarily due to lower revenue in the industrial Technology segment as a result of significantly reduced revenues in the environmental products markets, which the Company has decided to exit.
Gross Profit for the six months ended March 31, 2019 was $16,444,514 or 40% of revenues as compared to gross profit of $17,907,802 or 34% of revenues for the six months ended March 31, 2018. Gross profit as a percentage of revenues in the six months ended March 31, 2019 increased as compared to the six months ended March 31, 2018 as the Company works to achieve economies of scale, lower expenses, and shift to products and services with higher margins.
Net income available to common shareholders for the six months ended March 31, 2019 and 2018 was a loss of $5,117,947 and income of $1,155,462, respectively, a decrease of $6,273,409, or 543%.
Cemtrex’s Chairman and CEO, Saagar Govil, commented on the results, “This quarter saw our revenues increase with the growth in sales in our Advanced Technologies segment as we shift into technology businesses which provide higher gross margins and thus will allow us to generate better returns for our shareholders over the long term.
“The Company has now taken numerous steps to reduce the on-going loss and bring costs in line with expected revenues moving forward which will start to reflect in our next quarterly report. Our goal is to reach cash flow positive as soon as possible and eliminate the need to raise any further equity capital. This may result in longer timeframes to realize our growth targets, particularly around SmartDesk and VR activities, but ultimately will limit further dilution to common equity,” continued Mr. Govil.
About Cemtrex
Cemtrex, Inc. (CETX) is a global, multi-industry company that provides a wide array of solutions to meet today’s consumer, commercial, and industrial challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, integrated hardware and software solutions, industrial contracting services, and development of smart electronic devices. The Company also creates virtual reality and augmented reality applications.
www.cemtrex.com
$BIXT On Watch Red To Green ~ 72% Buy with a Average short term outlook on maintaining the current direction.
https://www.barchart.com/stocks/quotes/BIXT/overview
$OZSC Latest News : Ozop Surgical Corp to Present at the 9th Annual LD Micro Invitational
May 22, 2019
LOS ANGELES, CA / ACCESSWIRE / May 22, 2019 / Ozop Surgical Corp. (OTCQB: OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery today announced that it will be presenting at the 9th annual LD Micro Invitational on June 5th at 10:20am PST. Michael Chermak, CEO will be presenting and meeting with investors.
"This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever- growing community."
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.
About Ozop Surgical Corp.
Profiles powered by LD Micro - News Compliments of Accesswire
Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.
$XALL News Today ~ Xalles to Expand Financial Service Offerings
WASHINGTON, DC, May 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Xalles Holdings Inc. (XALL), a company focusing on accelerating fintech companies, leveraging blockchain technology for financial reconciliation, and payment auditing solutions, today announces the creation of a new wholly owned subsidiary, Xalles Financial Services Inc.
Xalles Financial Services is designed to develop and acquire financial services companies that will provide a variety of financial services in innovative ways to consumers and businesses. This newly formed platform will bring financial services to people in ways they have never experienced before. This will include bringing financial concepts such as participation in investment funds, cryptocurrencies, security tokens, stocks and bonds, and advanced banking, to a broader audience and through unique delivery methods and mobile solutions, to enable most individuals similar financial opportunities that were once only available to the wealthiest people.
The Xalles team is developing synergies between these new financial service offerings and the distribution networks that are growing within the Fintech Accelerator Program subsidiaries, namely Co-Owners Rewards, Amazing Living, and the Global Savings Network. Xalles aims to take the mystery and accessibility limitations out of the new financial markets. It will use technology and innovation to simplify the user experience and deliver new financial services and solutions to consumers and businesses.
“Our team has taken a key step towards bringing innovative financial services to the many that were once only available to the few,” expressed Thomas Nash, Xalles Holdings CEO. He added, “Through Xalles Financial Services, we will bring big business opportunities to small businesses, and allow everyone the chance to participate in the new and growing wealth building segments of our industry without the consumers and entrepreneurs having to become an expert on all of these new areas.”
Xalles Holdings expects to report progress throughout 2019 about the development and growth of this exciting new business unit.
About Xalles Holdings Inc. (XALL)
Xalles Holdings Inc. is a holdings company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities to invest and accelerate growth in. Recently, the company has placed emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which will allow for the capture of recurring revenue streams over time. For more information visit: http://xalles.com
$HIPH @AmericanPremium The Explosive Growth in The Cannabis Beverage Industry Could Boost the Value of these Three Cannabis Stocks #love #instagood #stock #news from #frontpagestocks
$NBEV $KGKG $WMT $LRSV $CGC
http://ow.ly/zIcE50umFpK
$HIPH $NBEV $KGKG The Explosive Growth in Cannabis Beverage Could Boost the Value of these Three Cannabis Stocks http://www.premarketbuzz.com/uncategorized/over-1-million-people-in-line-for-bitcoin-trading-app/ #NASDAQ #UPLISTING
$VTXB News : How to Save a Million
Published May 22, 2019
http://vortexgreenenergy.com/how-to-save-a-million/
$BIXT Bioxytran Using Paradigm Changing Vital Sign That Can Measure Real Time Tissue Oxygen Balance In Emergency Medicine
Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure tissue balance in stroke, and to test the viability of an organ before transplantation
BIOXYTRAN, INC. (OTC:BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS). The monitoring device measures mitochondrial function and microcirculation hemodynamics that are integrated and displays the TMS and plots it versus time. The article, entitled "Oxygen Balance Homeostasis and Tissue Metabolic Score (TMS) of Patients In Emergency and Critical Care Medicine" was published by Prof. Avraham Mayevsky in Volume 1, Issue 2 in the Journal of Emergency Medicine and Care. The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer. Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health.
The premise of the article is that patients that are admitted to the operation rooms or intensive care units (ICUs) need real time monitoring of a new vital sign called TMS. Monitoring the TMS allows clinicians and surgeons an early warning sign into the health of most vital organs like the heart and brain. The article covers the evolution of the monitoring device and the inner workings of the MDX viewer. The device measures 4 parameters and uses an algorithm to calculate the Tissue Metabolic Score. The primary concept that underpins the technology is Oxygen Balance Homeostasis that dates back to 1914. The principal of Oxygen Balance Homeostasis is that organs are unable to increase their activity without a corresponding increase in oxygen consumption delivered by increased blood flow. Monitoring the TMS in certain less vital organs serves a proxy of tissue health in the most vital organs. The MDX viewer uses a minimally invasive multiparametric monitoring device connected to the patient's urethral wall via a 3-way Foley catheter to measure TMS. When vital organs in the body are stressed, blood flow is diverted from less vital organs to the most vital organs and the TMS will fall. These changes can be measured with the MDX viewer to track tissue oxygenation levels in vital organs. A key case study done in cardiovascular operated patients underwent bypass of the coronary arteries procedure. During this type of operation, the TMS of the Urethral wall decreased significantly and then recovered toward the end of the operation as expected.
"Measuring the level of tissue oxygenation in diseases and surgical procedures could have a profound effect in clinical research" said Dr David Platt, CEO of Bioxytran. "In the past, researchers trying to prove the efficacy of a procedure on a vital organ like the brain had to rely on surrogate markers such as cognitive tests which require large patient populations and relatively subjective tests. With the advent of the FDA approved MDX Viewer, researchers can now accelerate their studies using the TMS biomarker and likely save a lot of money in the process. Tissue oxygenation levels are also important in tissue regeneration, stem cell transplantation, tissue transplantation, and tissue viability. The licensing opportunities in this area are boundless. Bioxytran's initial focus will be for patients of a stroke, Acute Respiratory Deficiency Syndrome (ARDS), sepsis, and heart failure. The stroke market is estimated at 900,000 annually. Since there is an unmet medical need in the stroke indication, Bioxytran will be primarily focusing its efforts in advancing BXT-25 through the clinical trials."
About MDX Life Sciences Inc.
MDX Life Sciences, Inc. is a clinical stage biotechnology company developing autologous transplantation techniques for tissue and organ regeneration. The focus of the development programs is on Myocardial Ischemia, reperfusion injury, Epilepsy, Traumatic Brain Injury and neurodegenerative and neuromuscular diseases. These diseases include Huntington's Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer's Disease, and Parkinson Disease. Continuing research has linked these diseases to various malfunctions of the mitochondria. Mitochondrial transplantation is a procedure that can open up the possibilities of disease modifying treatments resulting in tissue regeneration which would be a clear clinical endpoint for almost all these diseases. Using the Total Metabolic Score (TMS) calculated by the MDX Viewer will open up a new era in monitoring of patients during operations as well as in the Intensive Care Units. For additional info on our MDX Lifesciences, please visit www.mdxlifesciences.com
About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25. To learn more, visit our website: http://www.Bioxytraninc.com
Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com
$RVIV Reviv3 Procare Company Appoints Heather Cornell as Director of Investor Relations
LOS ANGELES, California, May 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Reviv3 Procare Company (RVIV) announced today that Ms. Heather Cornell has joined the company as Director of Investor Relations. Ms. Cornell will lead Reviv3’s corporate communication of its strategies, corporate initiatives and roadmap to analysts and investors. Ms. Cornell has over 20 years of experience in communications, strategic marketing and leading presentations at conferences and corporate events.
“Heather brings a strong set of competencies to Reviv3 as we continue to enhance our communication and corporate relationship with the investment community and we are excited to have her join our team,” said Donald Starace, President of Reviv3. “Her addition to Reviv3 allows us to effectively share our company outlook and shareholder value proposition.”
Ms. Cornell commented, “I look forward to contributing my expertise in corporate engagement and communication to Reviv3 during this remarkable period for the company. I will work to proactively anticipate and address investor focus areas and maintain a strong relationship of trust and respect with the investor community.”
About Reviv3 Procare Company
Reviv3 Procare Company is engaged in the manufacturing, marketing, sales, and distribution of professional quality hair and skin care products under various trademarks and brands. We are committed to using the highest quality active ingredients found in nature to create professional grade products that simply work. Our products are sold in targeted markets in the United States, Canada, Europe, and Asia.
https://finance.yahoo.com/news/reviv3-procare-company-appoints-heather-120000671.html
$CETX News : Cemtrex, Inc. (CETX) Announces Results for the Second Quarter ended March 31, 2019
LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--
Sales and Gross Profit for the quarter increased by 16% and 11% respectively
Cemtrex Inc. (CETX), a leading global technology company, announced its second quarter consolidated results of operations for the three and six months ended March 31, 2019.
Second Quarter Highlights:
Total Revenue for the three months ended March 31, 2019 and 2018 was $23,607,497 and $20,413,296, respectively, an increase of $3,194,201, or 16%. Total revenue in the second quarter increased, as compared to total revenue in the same period last year, primarily due to new revenues in the Advanced Technologies Segment, which had no revenues during the same period last year.
Gross Profit for the three months ended March 31, 2019 was $9,449,392 or 40% of revenues as compared to gross profit of $7,383,310 or 36% of revenues for the three months ended March 31, 2018, a percentage basis increase of 11%. Gross profit as a percentage of revenues in the three months ended March 31, 2019 increased as compared to the three months ended March 31, 2018 as the Company works to achieve economies of scale, lower expenses, and shift to products and services with higher margins.
Net income available to common shareholders for the three months ended March 31, 2019 and 2018 was a loss of $1,983,867 and income of $423,471, respectively, a decrease of $2,407,338, or 568%. Net income available to common shareholders decreased due to increased expenses in sales and marketing for the SmartDesk and VR applications in the Advanced Technologies segment as well as the consolidation of the variable interest entity, Vicon Industries, Inc.,
Six Month Ended March 31, 2019 Financial Highlights
Total revenue for the six months ended March 31, 2019 and 2018 was $40,892,041 and $52,795,196, respectively, a decrease of $11,903,155, or 23% primarily due to lower revenue in the industrial Technology segment as a result of significantly reduced revenues in the environmental products markets, which the Company has decided to exit.
Gross Profit for the six months ended March 31, 2019 was $16,444,514 or 40% of revenues as compared to gross profit of $17,907,802 or 34% of revenues for the six months ended March 31, 2018. Gross profit as a percentage of revenues in the six months ended March 31, 2019 increased as compared to the six months ended March 31, 2018 as the Company works to achieve economies of scale, lower expenses, and shift to products and services with higher margins.
Net income available to common shareholders for the six months ended March 31, 2019 and 2018 was a loss of $5,117,947 and income of $1,155,462, respectively, a decrease of $6,273,409, or 543%.
Cemtrex’s Chairman and CEO, Saagar Govil, commented on the results, “This quarter saw our revenues increase with the growth in sales in our Advanced Technologies segment as we shift into technology businesses which provide higher gross margins and thus will allow us to generate better returns for our shareholders over the long term.
“The Company has now taken numerous steps to reduce the on-going loss and bring costs in line with expected revenues moving forward which will start to reflect in our next quarterly report. Our goal is to reach cash flow positive as soon as possible and eliminate the need to raise any further equity capital. This may result in longer timeframes to realize our growth targets, particularly around SmartDesk and VR activities, but ultimately will limit further dilution to common equity,” continued Mr. Govil.
About Cemtrex
Cemtrex, Inc. (CETX) is a global, multi-industry company that provides a wide array of solutions to meet today’s consumer, commercial, and industrial challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, integrated hardware and software solutions, industrial contracting services, and development of smart electronic devices. The Company also creates virtual reality and augmented reality applications.
www.cemtrex.com
https://finance.yahoo.com/news/cemtrex-inc-cetx-announces-results-215000348.html
$XALL MOVING GREEN 0.0138+0.0048 (+53.2222%)
Volume 8,334,675
$MFST Medifirst Solutions Completes Time Machine Laser Sales for Two New Markets
Freehold, NJ, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Pharma CBD, is pleased to provide a laser sales update.
Medifirst Solutions is pleased to announce that a high school in Nebraska has successfully completed a test trial using the Time Machine Therapeutic Laser for sports related injuries. After extensive usage, the trial resulted in very positive results with injuries ranging from minor or serious. Working in conjunction with a Physical Therapist at the school, the medical professionals on site specifically saw substantial improvement with students with various Achilles injuries including post-surgical recovery. Satisfied with the positive results, the school purchased its first laser for sport related injuries. Commented Medifirst President Bruce J. Schoengood, “Using the laser for sports injuries and having a school purchase a unit, both opens a new market as well as continues to validate the positive results we see every day with our laser. Sports injuries are most often associated with immediate pain and swelling and we believe our laser can be a very effective tool for medical professionals treating such injuries.”
Medifirst Solutions is also pleased to announce that after an extensive and successful trial, a Florida based Obstetrician-gynecologist (OB-GYN) has purchased the Time Machine Infrared Laser. The trial feedback indicated positive results for reduced scarring after C-sections as well as positive results as related to intravaginal tissues associated with inflammation and cysts. Continued Mr. Schoengood, “We are very excited to receive positive feedback from physicians including a purchase of our laser. There are over one million C-sections every year in the US and this represents a potential whole new market for the Time Machine Laser.”
Dr. Ronald L. Rubin, Medical Director for Medifirst, commented, “I believe the Time Machine Laser is an important tool for physicians and healthcare professionals in the battle to decrease and eliminate pain in the great majority of injuries whether at home, work, car or on the playing field. I am thrilled to see my colleagues see first-hand the great results I have seen for the last several years. We will continue to work with doctors of all specialties to expand the use and cope of our therapeutic laser.”
About the Time Machine Laser
The Time Machine Laser is the only all-in-one, affordable, FDA cleared, Infrared, 810nm, 2000mW power, small, hand-held portable laser marketed for pain relief in the U.S. The Time Machine Laser, which has been extensively tested and approved by Intertek for safety and electrical standards, has the power and frequency often found in large and expensive stationary units and at a fraction of the cost. Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Laser is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
https://finance.yahoo.com/news/medifirst-solutions-completes-time-machine-130000584.html
$XALL Xalles Holdings Inc (XALL)
Overall Average:
100% BUY
https://www.barchart.com/stocks/quotes/XALL/opinion
$VTXB News ! Vortex Brands Moving Forward With Production of Phase Angle Synchronization Units
SACRAMENTO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Vortex Brands Co. (VTXB) announced today that the company will begin initial production of their signature product.
CEO Todd Higley stated, "We are pleased to announce that our demo unit has been moved to Bellingham, Washington where it will be housed in the research and development facility. The demo will serve as a test unit as we begin the process of production. We will begin with production and testing of wiring harnesses for the units designated for our pilot programs."
Mr. Higley went on to say, "We have narrowed our focus down to two key strategic locations for implementing pilot operations. We have had significant interest in Northern California for months now and as of late, there has been an increase in interest coming out of Detroit, Michigan. We feel strongly that we should start where the interest is solid and where implementation will be as smooth as possible and these two locations should prove to be advantageous."
Mr. Higley finished up with, "The announcements we will be making over the next few weeks and months are the culmination of years of work."
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.
Source: Vortex Brands Co.
Contact: info@vortexbrands.us
$VTXB Vortex Brands Moving Forward With Production of Phase Angle Synchronization Units
SACRAMENTO, Calif., May 15, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Vortex Brands Co. (USOTC: VTXB) announced today that the company will begin initial production of their signature product.
CEO Todd Higley stated, “We are pleased to announce that our demo unit has been moved to Bellingham, Washington where it will be housed in the research and development facility. The demo will serve as a test unit as we begin the process of production. We will begin with production and testing of wiring harnesses for the units designated for our pilot programs.”
Mr. Higley went on to say, “We have narrowed our focus down to two key strategic locations for implementing pilot operations. We have had significant interest in Northern California for months now and as of late, there has been an increase in interest coming out of Detroit, Michigan. We feel strongly that we should start where the interest is solid and where implementation will be as smooth as possible and these two locations should prove to be advantageous.”
Mr. Higley finished up with, “The announcements we will be making over the next few weeks and months are the culmination of years of work.”
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.
Source: Vortex Brands Co.
Contact: info@vortexbrands.us
https://www.smallcapvoice.com/vortex-brands-moving-forward-with-production-of-phase-angle-synchronization-units/
AMERICAN PREMIUM WATER CORPORATION (OTC: $HIPH) ANNOUNCES JOINT VENTURE WITH CBD PET PRODUCT MANUFACTURER LINKRES PETS (OTC: $LRSV) TO PRODUCE CBD PET WATER
http://gototc.com/american-premium-water-corporation-otc-hiph-announces-joint-venture-with-cbd-pet-product-manufacturer-linkres-pets-otc-lrsv-to-produce-cbd-pet-water/
$VTXB NEWS OUT ~ Vortex Brands Moving Forward With Production of Phase Angle Synchronization Units
SACRAMENTO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Vortex Brands Co. (VTXB) announced today that the company will begin initial production of their signature product.
CEO Todd Higley stated, "We are pleased to announce that our demo unit has been moved to Bellingham, Washington where it will be housed in the research and development facility. The demo will serve as a test unit as we begin the process of production. We will begin with production and testing of wiring harnesses for the units designated for our pilot programs."
Mr. Higley went on to say, "We have narrowed our focus down to two key strategic locations for implementing pilot operations. We have had significant interest in Northern California for months now and as of late, there has been an increase in interest coming out of Detroit, Michigan. We feel strongly that we should start where the interest is solid and where implementation will be as smooth as possible and these two locations should prove to be advantageous."
Mr. Higley finished up with, "The announcements we will be making over the next few weeks and months are the culmination of years of work."
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.
Source: Vortex Brands Co.
Contact: info@vortexbrands.us
https://finance.yahoo.com/news/vortex-brands-moving-forward-production-130000837.html
$BOXS BoxScore Brands reposition its product offerings and focus on consumer products with Cannabidiol ("CBD") and other alternative wellness products.
BoxScore Brands Management Announces Distribution Deal with Pellequr LLC.
GlobeNewswire•April 30, 2019
Las Vegas, NV, April 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BoxScore Brands, Inc., (BOXS), announced a distribution deal with Pellequr LLC, a Beverly Hills, CA based spa and manufacturer of CBD related skin and wellness products.
Michael Flanagan, newly appointed CEO of BoxScore Brands, stated, “Pellequr makes the best products in each category they operate. When we looked at value added niche products in the skincare category, Pellequr’s array of products was our first choice to partner with as our initial offering.”
The US Skincare market is estimated at +$17 billion and growing annually. The integration of CBD into skin care and beauty products is also proving success through customer adoption. Flanagan stated, “We will be taking what Pellequr does so well in their Beverly Hills spa and introducing to the broader US market through existing relationships. Celebrities and influencers have flocked to Pellequr simply because the products are better than anything else in the market.”
Founded in 2018, Pellequr, LLC opened a spa to modernize age-old Korean traditions to launch the newest and ultimate experience in luxury skin care. The company uses innovative techniques and detoxification from its expert technicians using proprietary products that are infused with the transformative healing powers of CBD oil. The company has developed a series of products based around CBD oil. (Instagram @pellequr)
Founded in 2007, BoxScore Brands served +300 points of sale in California and Nevada through automated frozen vending machines and reach in freezers. In April 2019, the BoxScore Brands reposition its product offerings and focus on consumer products with Cannabidiol ("CBD") and other alternative wellness products.
BoxScore Brands, Inc. will market and distribute Pellequr products globally.
ABOUT BOXSCORE™ BRANDS, INC.
BoxScore ™ Brands, Inc, headquartered in Las Vegas, NV, is a consumer products and technology company that develops, distributes, and consumer products in the United States. For more information visit https://boxscore.com/ or call (855) 558-8363 or e-mail ir@boxscore.com.
$AMHV AMHV's mission is to become the world's preeminent, vertically integrated "seed-to-table" hemp operation. AMHV develops hybrid hemp cultivars that are genetically designed to produce high CBD yields in a wide variety of geographies. We apply our proprietary seed feminization process to further increase crop production as much as 100%.
American Hemp Ventures, Inc. (OTC: AMHV) expands Consulting and Grow Operations by 140% in Q1
PR Newswire PR NewswireApril 3, 2019
AURORA, Colo., April 3, 2019 /PRNewswire/ -- American Hemp Ventures, Inc. ("AMHV") , has added over 320,000 sq. ft of greenhouse grow operations under management dedicated to seed production during the 1st quarter of 2019. The expanded grow operations represent an increase of approximately 140% over 2018-year end. Total grow operations will now include over 540,000 sq. ft of hemp greenhouses dedicated to the production of AMHV's 4 proprietary high CBD hemp seed cultivars and the associated biomass. Current grow operations are expected to yield over 100 Million seeds per year and an estimated 50,000 lbs. of high CBD biomass.
American Hemp Ventures, Inc.
AMHV's mission is to become the world's preeminent, vertically integrated "seed-to-table" hemp operation. AMHV develops hybrid hemp cultivars that are genetically designed to produce high CBD yields in a wide variety of geographies. We apply our proprietary seed feminization process to further increase crop production as much as 100%.
The Company's subsidiaries have developed deep expertise in hemp-growing techniques and have developed various proprietary hemp cultivars, as well as a proprietary process to feminize hemp seed. The company's operations are focused on sales of hemp seed, hemp bio mass and CBD distillate, a line of CBD infused retail products, as well as providing consulting services and generating royalties from consulting clients.
AMHV currently operates three primary business streams; a) LTC Farms for the growing and cultivation of Hemp for its own account using proprietary seed types, and b) HEMP Consulting Group which provides a turnkey service to farmers and investors wishing to grow Hemp on their own land, and 3) AMHV Wellness that has developed and sells topical and nutritive CBD products for consumers and pets. Our turnkey Consulting service typically generates both consulting fees and a participation revenue.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully market our products and services; the acceptance of our products and services by customers and clients; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other companies in our industry; the effects of changes in the cannabis industry and markets; our ability to successfully develop new products and services; our success establishing and maintaining client, customer and supplier relationships; our ability to comply with applicable regulations; and other risks and uncertainties relating to our business. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
$MFST News Freehold, NJ, May 08, 2019 Medifirst Solutions Completes Time Machine Laser Sales for Two New Markets
https://finance.yahoo.com/news/medifirst-solutions-completes-time-machine-130000584.html
$CETX News : Cemtrex Announces NASDAQ and Henry Schein as Latest SmartDesk Customers
Long Island City, NY, April 09, 2019 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a leading global technology company, today announced that it has added NASDAQ, Inc. and Henry Schein, Inc as its latest SmartDesk Enterprise clients. Both companies have bought SmartDesks to evaluate the product for widescale use in their organizations. NASDAQ is one the world’s most recognized companies, operating many of the world’s stock market exchanges, with over 4500 employees globally.
https://finance.yahoo.com/news/cemtrex-announces-nasdaq-henry-schein-124000087.html
$BIXT NEWS: Bioxytran Inc. Announces Appointment of Ex Bristol-Myers Squibb Executive to Scientific Advisory Board
BOSTON, MASSACHUSETTS, May 06, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that it has retained Juan Carlos Lopez-Talavera, MD, PhD to join Bioxytran’s Scientific Advisory Board to manage the company’s FDA regulatory application process for Bioxytran’s flagship drug, BXT-25.
“Dr. Lopez-Talavera will play an important role in overseeing our new drug through the FDA’s regulatory process,” stated Bioxytran CEO, David Platt. “Juan has been instrumental in expediting well known drugs such as OCALIVA® through the regulatory process. We believe that Juan’s personal and professional relationships with some of the top pharmaceutical companies and Key Opinion Leaders will bring great value to Bioxytran. His experience in tissue regeneration will bring great skills to our FDA application process and designing our trials for Ischemic Stroke. Bioxytran is truly fortunate to acquire talent of such a high caliber.”
“Dr. Lopez-Talavera has a reputation of developing disruptive technologies which we believe is critical for compounds such as Bioxytran’s BXT-25. It is rare to obtain such a qualified candidate in a developmental stage company like Bioxytran, and we view it as an endorsement of our plans for BXT-25.”
Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, as Vice President and Global Development Lead, and Roche Laboratories as Senior Medical Director. Before moving into the industry, Dr. Lopez-Talavera was an Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center, Associate Professor of Medicine with the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.
“In my professional career I have always gravitated toward working with novel mechanisms. “ said Dr. Lopez-Talavera. ”The opportunity at Bioxytran is so vast, because tissue oxygenation represents a true unmet medical need and represents a tremendous untapped opportunity to target both the Ischemic Stroke and, has future potential for Acute Respiratory Distress Syndrome (“ARDS”). BXT-25 has the unique ability to deliver oxygen through a small molecule which can be effective in extending the “golden hour” in stroke victims and potentially for tissue regeneration in ARDS victims. I am honored to be part of this team and look forward to advancing the science and creating partnerships or joint ventures that will grow this field of research.”
Dr. Lopez-Talavera was a Postdoctoral Fellow at the Yale University School of Medicine, and Clinical Observer at Sloan Kettering Memorial Cancer Center. He holds an M.D. and a Ph.D. in Hepatology from the Universidad Autónoma de Barcelona.
About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. To learn more, visit our website: http://www.Bioxytraninc.com
$DSCR Mining Operations on War Eagle Mountain will Commence late June on a near surface section of the Oro Fino Trench @frontpagestocks
https://ih.advfn.com/stock-market/USOTC/discovery-minerals-ltd-pn-DSCR/stock-news/79874708/mining-operations-on-war-eagle-mountain-will-comme @frontpagestocks
$OZSC ON ALERT ~ Ozop Surgical Corp to Present at the Spring Investor Summit on April 1st and 2nd in New York City at the Essex House
WEST PALM BEACH, FL / ACCESSWIRE / March 25, 2019 / Ozop Surgical Corp. (OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery will be presenting at this year's Spring Investor Summit on April 2nd at 11:00 AM EST in New York City.
The Spring Investor Summit (formerly The MicroCap Conference) is an exclusive event dedicated to connecting small and micro cap companies with high-level, institutional and retail investors.
The Spring Investor Summit will take place in New York City at the Essex House on April 1st and 2nd. The upcoming conference will feature 200 presenting companies, 1,200 institutional and retail investors, 2,000 one-on-one meetings, expert speakers, and industry panels.
To request free registration, please go to (www.springinvestorsummit.com), and click the "Registration" button
About Ozop Surgical Corp.
Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.
Safe Harbor Statement
"This press release contains or may contain, among other things, certain forward-looking statements. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties, including those detailed in the company's filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the company's control). The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law."
Investor Relations:
Ted Haberfield
President
MZ Group - MZ North America
(760) 755-2716
thaberfield@mzgroup.us
www.mzgroup.us
SOURCE: Ozop Surgical Corp.
View source version on accesswire.com:
https://www.accesswire.com/540066/Ozop-Surgical-Corp-to-Present-at-the-Spring-Investor-Summit-on-April-1st-and-2nd-in-New-York-City-at-the-Essex-House
$RVIV NEWS : Reviv3 Procare Company Appoints Heather Cornell as Director of Investor Relations
LOS ANGELES, California, May 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Reviv3 Procare Company (RVIV) announced today that Ms. Heather Cornell has joined the company as Director of Investor Relations. Ms. Cornell will lead Reviv3’s corporate communication of its strategies, corporate initiatives and roadmap to analysts and investors. Ms. Cornell has over 20 years of experience in communications, strategic marketing and leading presentations at conferences and corporate events.
“Heather brings a strong set of competencies to Reviv3 as we continue to enhance our communication and corporate relationship with the investment community and we are excited to have her join our team,” said Donald Starace, President of Reviv3. “Her addition to Reviv3 allows us to effectively share our company outlook and shareholder value proposition.”
Ms. Cornell commented, “I look forward to contributing my expertise in corporate engagement and communication to Reviv3 during this remarkable period for the company. I will work to proactively anticipate and address investor focus areas and maintain a strong relationship of trust and respect with the investor community.”
About Reviv3 Procare Company
Reviv3 Procare Company is engaged in the manufacturing, marketing, sales, and distribution of professional quality hair and skin care products under various trademarks and brands. We are committed to using the highest quality active ingredients found in nature to create professional grade products that simply work. Our products are sold in targeted markets in the United States, Canada, Europe, and Asia.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. The use of words such as “anticipates,” “expects,” “intends,” “plans,” “confident that” and “believes,” among others, generally identify as forward-looking statements.
These forward-looking statements are based on currently available information, management’s beliefs, future projections, and current expectations subject to a number of significant risks and uncertainties. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3’s ability to grow net sales and adjusted EBITDA as anticipated (ii) our ability to fund our operating expenses (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives; (iv) Reviv3’s ability to compete effectively with other hair and skin care companies (v) the concentration of Reviv3’s customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3’s product costs and other costs of doing business, and reduce Reviv3’s earnings. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Heather Cornell
888-638-8883
ir@reviv3.com
https://finance.yahoo.com/news/reviv3-procare-company-appoints-heather-120000671.html
$RGBP Regen BioPharma, Inc. Responds to Fake News Release
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (RGBP) and (RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Responding to these inquiries the Company reports that it is currently not in any discussions with any other companies regarding a reverse merger.
"This false news release was brought to my attention by a number of people. I have read the news release in question and can state that it is totally untrue," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. "We are focused on our own business model of small molecule immunotherapies for treating cancer and autoimmune disorders."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
$RVIV President of Reviv3 Procare Company Discusses Business Plan and Recent Financial Results in New Interview at SmallCapVoice.com
AUSTIN, Texas, May 07, 2019 (GLOBE NEWSWIRE) -- Reviv3 Procare Company (RVIV), today announce that Company president Donald Starace is featured in a new audio interview at SmallCapVoice.com.
The interview can be heard at: https://www.smallcapvoice.com/5-3-19-smallcapvoice-interview-with-reviv3-procare-company-rviv/.
Starace called in to SmallCapVoice.com to discuss the Company’s premium line of hair care products made from the highest quality natural ingredients, the management team’s extensive background in the hair care market, the strong financial footing for the company and much more. Recently, the Company posted their Q3 2019 numbers. Highlights include;
Revenues increased by 28% compared to the same comparable period in 2018.
Gross profit as a percentage of revenues increased to 43% compared to 38% for the same period in 2018.
Operating Expenses for the 3 months decreased by 36% to the same comparable period in 2018.
"These numbers show why we were so excited to be speaking with SmallCapVoice.com. We are extremely optimistic about our future with the foundation we have built over the last couple of years," stated Starace. " Once again, we are thankful for the opportunity to share our story with our followers and the SmallCapVoice.com listening audience.”
About SmallCapVoice.com Inc.
SmallCapVoice.com Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and its services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/
About Reviv3
Reviv3 Procare Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands. We are committed to using the highest quality active ingredients found in nature to create professional grade products that simply work. Our products are sold in targeted markets in United States, Canada, Europe, and Asia.
Forward-Looking Statements
This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as “anticipates,” “expects,” “intends,” “plans,” “confident that” and “believes,” among others, generally identify forward-looking statements.
These forward-looking statements are based on currently available information, and management’s belief, projections, and current expectations subject to a number of significant risks and uncertainties. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3’s ability to grow net sales and adjusted EBITDA as anticipated; (ii) our ability to fund our operating expenses (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives; (iv) Reviv3’s ability to compete effectively with other hair and skin care companies (v) the concentration of Reviv3’s customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3’s product costs and other costs of doing business, and reduce Reviv3’s earnings. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Company Contact:
Christopher Go
888-638-8883
cgo@reviv3.com
SmallCapVoice.com Contact
Stuart T. Smith
512-267-2430
SSmith@SmallCapVoice.com
$BOXS BoxScore Brands Management Announces Distribution Deal with Pellequr LLC.
Las Vegas, NV, April 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BoxScore Brands, Inc., (BOXS), announced a distribution deal with Pellequr LLC, a Beverly Hills, CA based spa and manufacturer of CBD related skin and wellness products.
Michael Flanagan, newly appointed CEO of BoxScore Brands, stated, “Pellequr makes the best products in each category they operate. When we looked at value added niche products in the skincare category, Pellequr’s array of products was our first choice to partner with as our initial offering.”
The US Skincare market is estimated at +$17 billion and growing annually. The integration of CBD into skin care and beauty products is also proving success through customer adoption. Flanagan stated, “We will be taking what Pellequr does so well in their Beverly Hills spa and introducing to the broader US market through existing relationships. Celebrities and influencers have flocked to Pellequr simply because the products are better than anything else in the market.”
Founded in 2018, Pellequr, LLC opened a spa to modernize age-old Korean traditions to launch the newest and ultimate experience in luxury skin care. The company uses innovative techniques and detoxification from its expert technicians using proprietary products that are infused with the transformative healing powers of CBD oil. The company has developed a series of products based around CBD oil. (Instagram @pellequr)
Founded in 2007, BoxScore Brands served +300 points of sale in California and Nevada through automated frozen vending machines and reach in freezers. In April 2019, the BoxScore Brands reposition its product offerings and focus on consumer products with Cannabidiol ("CBD") and other alternative wellness products.
BoxScore Brands, Inc. will market and distribute Pellequr products globally.
ABOUT BOXSCORE™ BRANDS, INC.
BoxScore ™ Brands, Inc, headquartered in Las Vegas, NV, is a consumer products and technology company that develops, distributes, and consumer products in the United States. For more information visit https://boxscore.com/ or call (855) 558-8363 or e-mail ir@boxscore.com.
Forward Looking Statements: This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
$RGBP Regen BioPharma, Inc. Responds to Fake News Release
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (RGBP) and (RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Responding to these inquiries the Company reports that it is currently not in any discussions with any other companies regarding a reverse merger.
"This false news release was brought to my attention by a number of people. I have read the news release in question and can state that it is totally untrue," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. "We are focused on our own business model of small molecule immunotherapies for treating cancer and autoimmune disorders."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com